Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
CAMBRIDGE, Mass., April 27, 2017 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, May 4, 2017 at 8:00 a.m. ET to report its first quarter 2017 financial results and discuss recent clinical development and corporate activities.
The live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and refer to conference ID 13557397. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Agios Pharmaceuticals: Kendra Adams, 617-844-6407 Senior Director, Investor & Public Relations [email protected] Renee Leck, 617-649-8299 Senior Manager, Investor & Public Relations [email protected]
